Alkermes has been granted a patent for a pharmaceutical composition that ensures long-term stability of a hydrolytically labile antipsychotic agent. The composition includes Compound 1. GlobalData’s report on Alkermes gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Alkermes, was a key innovation area identified from patents. Alkermes's grant share as of April 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Long-term stable pharmaceutical composition with hydrolytically labile antipsychotic agent
The granted patent (Publication Number: US11969469B2) discloses a pharmaceutical composition comprising Compound 1 as a key ingredient. The composition is formulated to contain less than 30 parts per million of the hydrolysis product of Compound 1 after standing for at least 24 months. Additionally, the composition includes a water miscible and/or soluble non-ionic surfactant, specifically a polyoxyethylene derivative of a sorbitan ester of a carboxylic acid with 8-14 carbon atoms, such as sorbitan laurate or polysorbate 20.
Furthermore, the patent claims a pharmaceutical composition with 15-35 weight percent of compound I as a crucial component. The formulation aims to minimize the presence of the hydrolysis product of Compound 1 to ensure stability and efficacy over an extended period. By specifying the type of non-ionic surfactant and the concentration of the active ingredient, the patent provides a clear framework for the development of pharmaceutical compositions with improved shelf-life and performance.
To know more about GlobalData’s detailed insights on Alkermes, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.